Cannabis Science Inc  

(Public, OTCMKTS:CBIS)   Watch this stock  
Find more results for PINK:CBIS
-0.0010 (-1.21%)
After Hours: 0.0806 0.0000 (0.00%)
Apr 21, 4:00PM EDT  
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.08 - 0.08
52 week 0.01 - 0.14
Open 0.08
Vol / Avg. 18.77M/20.17M
Mkt cap 202.16M
P/E     -
Div/yield     -
EPS -0.01
Shares 2.39B
Beta -2.77
Inst. own 0%

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 276077.00% -107886.60%
Operating margin 451645.90% -93846.55%
EBITD margin - -85158.10%
Return on average assets 719.31% -666.61%
Return on average equity - -
Employees 5 -
CDP Score - -


19800 Macarthur Blvd Ste 300
IRVINE, CA 92612-2479
United States - Map
+1-888-8890888 (Phone)

Website links


Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company's subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Officers and directors

Raymond C. Dabney President, Chief Executive Officer, Director
Age: 51
Benjamin C.K. Tam Chief Financial Officer, Secretary, Director
Robert Kane Chief Operating Officer, Director
Age: 40
Mario Lap Director
Age: 64